<img alt="" src="https://secure.lote1otto.com/219869.png" style="display:none;">
Skip to content

De-Risking Drug Development using Adaptive Design

The VALOR trial recently applied a promising zone design to a Phase 3 evaluation of Vosaroxin, a candidate for the treatment of relapsed/refractory acute myeloid leukemia. CMO Dr. Adam Craig reports that there were intial anxieties about financing a trial that required 800 patients. However, a promising interim look raised investors' confidence in the treatment's success, leading to a high-powered trial of 712 patients.

 Promising_zone2017

To view a YouTube video of Dr. Adam Craig talking about the Phase 3 VALOR trial, click below.  

 
  

Cytel Videos Adam Craig on the Phase 3 VALOR trial:  Adaptive Sample Size Re-estimation

 

 

 

contact iconSubscribe back to top